Having trouble accessing articles? Reset your cache.

GLPG0634: Phase II data

Furthermore, once- and twice-daily GLPG0634 led to ACR50 response rates of 25% and 58.3%, respectively, vs. 8.3% for placebo (p=0.0591 for pooled data vs. placebo), while ACR70 response rates were 16.7% and 25%, respectively, vs. 0%

Read the full 361 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE